940875-74-1

Upstream product

• 19501-58-7 4-methoxyphenylhydrazine hydrochloride 
• 59997-51-2 trimethylacetylacetonitrile 
• 227623-26-9 3-tert-butyl-1-(4-methoxyphenyl)-1H-pyrazol-5-amine 
• 17341-93-4 2,2,2-Trichloroethyl chloroformate 

Downstream Products

• 1443247-13-9 1-(5-tert-butyl-2-(4-methoxy-phenyl)-2H-pyrazol-3-yl)-3-[(1S,4R)-4-(3-isopropyl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea 

Relevant academic research and scientific papers

Synthesis and p38 inhibitory activity of some novel substituted N,N′-diarylurea derivatives

We have identified a novel series of substituted N,N′-diarylurea p38α inhibitors. The inhibitory activity of the target compounds against the enzyme p38α, MAPKAPK2 in BHK cells, TNF-α release in LPS-stimulated THP-1 cells and p38α binding experiments were

POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES

The current invention provides urea derivatives, in particular compounds having the core structure heteroaryl-NH-CO-NH-aryl-O- heteroaryl, for use in treating, ameliorating, delaying, curing and/ or preventing a disease or condition associated with muscle cells and/or satellite cells, such as Duchenne muscular dystrophy, Becker muscular dystrophy, cachexia or sarcopenia.